🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07259434
Starting soon Not applicable

Time Restricted Eating in Survivors Trial 2.0

NCT07259434 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-01-01
Last updated
2025-12-02

Condition(s) studied

Breast CancerCardiovascular RiskCognitive FunctionPhysical Function

Investigational drug(s) / intervention(s)

Time Restricted EatingHealthy Eating Education

Time Restricted Eating: Participants receive remote counselling on TRE and protein intake. A registered dietitian (RD) will provide counselling on protein intake to mitigate potential decreases seen with TRE. The RD will provide participants with an individualized protein intake goal and will encourage them to work toward, or maintain, consuming at least 1.2 g/kg/day. Participants will receive a reference manual with a list of foods, serving sizes and protein content to help with achieving their protein intake goal. During the intervention, participants will be asked to respond to twice-daily automated text messages with the times they started and stopped eating on that day. TRE adherence will be determined as % of days where participant responses indicate fasting for ≥16h. Protein intake adherence assessed by the RD from the 24-h diet recall. Participants will also be asked to respond with a Likert ranking (1-5) to nutrition-related texts stemming from Health Canada dietary recommendations (same as control).

Healthy Eating Education: The initial call (week 0) will focus on healthy eating education. Each check-in call will include continued healthy eating education, collection of adverse events related to the intervention and assessment of TRE contamination (via 24-h diet recall and reporting of number and timing of meals). This information will be recorded for comparison to the TRE group and across the intervention period. To standardize the use of daily text messages and enhance study engagement, participants in the TRE and the healthy eating education groups will both be asked to respond with a Likert ranking (1-5) to a nutrition-related question stemming from the Health Canada dietary recommendations on healthy eating (e.g. "Enjoying your food is part of healthy eating. How much do you enjoy the taste of your food?" Respond with 1 to 5 where 1=do not enjoy and 5=enjoy very much).

Study summary

After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.

Eligibility

Sex
FEMALE
Min age
60 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * female * aged 60-85 years * BMI ≥25 kg/m2 * diagnosed with early-stage (I-III) BC in the past 15 years * received chemotherapy treatment that was completed ≥1 year earlier * Montreal Cognitive Assessment (MoCA) score of 10-30 which aligns with no impairment to moderate impairment thresholds. Exclusion Criteria: * does not have a mobile device that connects to Bluetooth and can send/receive text messages * history of physician-diagnosed heart disease, dementia or Alzheimer's disease, diabetes that requires insulin or sulfonylurea usage, or eating disorder * MoCA total score \<10 (indicating dementia) * ≥5kg weight change within past 3 months * taking lipid- or weight-lowering medication (e.g. statins or GLP-1 agonists) * high-risk for malnutrition (≥3 on the Malnutrition Screening Tool) * research MRI contraindications (e.g., pacemaker, breast tissue expander, magnetic implants) * eating all daily calories in \<10h/d in the past 3 months * following a structured dietary practice (e.g., ketogenic diet, Weight Watchers) or actively trying to lose weight in the past 3 months * being unable to make adjustments to eating time or nutrient intake * regularly doing \>90 min/week of moderate physical activity in the past 3 months * severe claustrophobia * BMI\>40 kg/m2 (due to body habitus fit within MRI scanner bore) * major psychiatric disorders (e.g. bipolar, post-traumatic stress disorder, schizophrenia) * neurological disorders that significantly impact physical or cognitive function (epilepsy, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy) or traumatic brain injury resulting in ongoing neurological deficits. If the screening process identifies patients with undiagnosed severe cognitive function (MoCA score \<10) or at high risk for malnutrition (≥3 on the Malnutrition Screening Tool), the investigators will recommend that the individual see their family physician. In this process, the investigators will ask the participant if there is a family member that can also receive this information.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Toronto Toronto Ontario

More University of Toronto trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07259434 on ClinicalTrials.gov ↗ ← All trials in Canada